Results 91 to 100 of about 1,763 (188)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

open access: yes, 2020
Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival.
Gaissmaier, Lena   +31 more
core   +1 more source

Multidisciplinary approach with stereotactic reirradiation to oligoprogressive spinal metastases from dedifferentiated osteosarcoma: a case report

open access: yesFrontiers in Oncology
BackgroundStereotactic body radiotherapy (SBRT) has emerged as a promising therapeutic approach for vertebral metastases, achieving high local control and safety.
Arkadiusz Moskwa   +6 more
doaj   +1 more source

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT) [PDF]

open access: yes
BACKGROUND: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who completed two-years of ...
Warburton, L   +11 more
core   +2 more sources

Case Report: Complete metabolic response to alectinib in a TNS1-ALK-rearranged uterine inflammatory myofibroblastic tumor, with stereotactic body radiotherapy for oligoprogression

open access: yesFrontiers in Pharmacology
Inflammatory myofibroblastic tumors of the uterus harboring a TNS1-ALK fusion are rare, and their response to the anaplastic lymphoma kinase (ALK) inhibitor alectinib, including the management of oligoprogression with stereotactic body radiotherapy, is ...
Hakan Özçelik   +4 more
doaj   +1 more source

Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)

open access: yes
Objective Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a new standard of care for the maintenance treatment of advanced epithelial ovarian cancer.
Rigo, Michele   +14 more
core   +1 more source

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

open access: yes, 2019
International audienceBackgroundStereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from lung cancer but is controversial for extracranial oligometastases. We assessed outcomes of lung cancer
Stefan, Dinu   +27 more
core   +1 more source

Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma [PDF]

open access: yesONCOLOGY, 2021
Nora, Sobrevilla-Moreno   +5 more
openaire   +2 more sources

Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.

open access: yes, 2017
e587 Background: SABR is increasingly used for the treatment of men with oligometastatic prostate cancer, including patients (pts) presenting with oligoprogression.
Vanessa S. Arciero   +6 more
core   +1 more source

Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases

open access: yesRadiation
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstrated.
Emanuele Chioccola   +11 more
doaj   +1 more source

Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases

open access: yesScientific Reports
Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients ...
Paweł Cisek   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy